Gossamer Bio Announces Data Presentations at the Virtual European Respiratory Society International Congress 2020

On September 7, 2020 Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, reported that it will present four posters with data relevant to its GB001 and GB002 programs at the Virtual European Respiratory Society International Congress 2020, which takes place from September 7th through 9th (Press release, Gossamer Bio, SEP 7, 2020, View Source [SID1234564705]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for presentations related to GB001, an oral DP2 antagonist for eosinophilic asthma and chronic rhinosinusitis (CRS), are as follows:

Session Type: E-Poster Session
Session Title: Clinical and laboratory pharmacology in asthma (Session 109)
Abstract Number: 2922
Poster Code: 1420
Poster Title: GB001 is a potent, insurmountable DP2 antagonist with long receptor residence time and extended pharmacodynamic effects
Link: View Source

Session Type: E-Poster Session
Session Title: Clinical and laboratory pharmacology in asthma (Session 109)
Abstract Number: 2915
Poster Number: 1421
Poster Title: GB001, a selective prostaglandin D2 receptor 2 antagonist, blocks signaling in the peripheral blood of healthy subjects
Link: View Source

Session Type: E-Poster Session
Session Title: Asthma science: novel targets and mechanisms (Session 193)
Abstract Number: 2885
Poster Number: 2902
Poster Title: GB001 potently inhibits PGD2 metabolite-induced DP2-mediated cell signaling and eosinophil activation
Link: View Source

Details for a presentation related to GB002, an inhaled PDGFR inhibitor for pulmonary arterial hypertension (PAH), are as follows:

Session Type: E-Poster Session
Session Title: Pathophysiology of pulmonary hypertension (Session 231)
Abstract Number: 2551
Poster Number: 3550
Poster Title: Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH)
Link: View Source